Processes for Virus-based Biologics

Published: 25-Mar-2014

2 - 3 June 2014

Conference

Schloss Grosslaupheim, Germany


Rentschler Biotechnologie announces the third Laupheimer Zelltage industrial cell culture conference, which will focus on Processes for Virus-based Biologics.

The event will encompass all aspects related to platform technologies for the manufacturing and control of viral biopharmaceuticals, including viral vectors, oncolytic viruses and virus-based vaccines.

Organiser: Rentschler Biotechnologie

www.laupheimer-zelltage.org

Trending Articles

  1. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US
  2. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  3. ASGCT Annual Meeting 2024 7-11 May, 2024 | Meeting | Portland, OR
  4. CPhI South East Asia 2024 10-12 July 2024 | Exhibition and Conference | Bangkok, Thailand
  5. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany

You may also like

Manufacturing

Rentschler Biotechnologie announces transition into EU corporation

Rentschler Biotechnologie, announced it has successfully transitioned into a European corporation (SE), Rentschler Biopharma SE, with entry into the German commercial register on 1 October, 2017
Manufacturing

Rentschler doubles manufacturing capacity to address growing demand for biopharmaceuticals

New facility offers innovative Twin system with two 3,000-litre bioreactors and associated downstream processing equipment in the company's second significant expansion in a year
Pharmaceutical

4th Laupheim Biotech Days

13 - 14 June 2016, Conference, Laupheim, Germany
Manufacturing

Stefan Rampf to take over as CFO at Rentschler on 1 May

He will be responsible for commercial management
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Employing new single-use technology in bioprocesses

There has been considerable progress in the application of single-use technologies in biopharmaceutical production. CMO Rentschler Biotechnologie discusses recent advances
Manufacturing

Rentschler invests €24m in stainless steel bioreactor manufacturing

Twin system should be operational in early 2017 and will more than double production capacities for cell culture-derived proteins
Pharmaceutical

Processes for Virus-based Biologics

2 - 3 June 2014, Conference, Schloss Grosslaupheim, Germany
Subscribe now